Skip to main content

Nanosphere Seeks to Raise $30.6M in Public Stock Offering

NEW YORK (GenomeWeb News) – Nanosphere on Friday said that it had filed to offer 4.7 million shares of its common stock in a public offering.

The Northbrook, Ill.-based molecular diagnostics firm priced the offering at $7 per share and expects net proceeds of $30.6 million from the offering — or $35.3 million if the over-allotment option of 705,000 shares is exercised. Nanosphere's shares closed Thursday unchanged at $7.65 on the Nasdaq.

Nanosphere did not specify its intended use of proceeds, other than saying such funds would be applied to general corporate purposes and working capital.

The firm sells the Verigene System, a molecular diagnostics platform that received US Food and Drug Administration clearance in 2007. The company also holds FDA clearance for a variety of assays for hypercoagulation, warfarin metabolism, and cystic fibrosis, as well as a respiratory virus panel.

Nanosphere also has filed for FDA clearance of a hemochromatosis assay and expects to file for clearance of a protein test for cardiac troponin I by the end of this year.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.